How to Manage Atrial Fibrillation Secondary to Ibrutinib

doi:10.1016/j.jaccao.2020.11.016

Review

. 2021 Mar 16;3(1):140-144.

doi: 10.1016/j.jaccao.2020.11.016. eCollection 2021 Mar.

How to Manage Atrial Fibrillation Secondary to Ibrutinib

Hani Essa¹, Taha Lodhi², Rebecca Dobson¹, David Wright¹, Gregory Y H Lip^{1

3}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
² Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
³ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

PMID: 34396314
PMCID: PMC8352308
DOI: 10.1016/j.jaccao.2020.11.016

Review

How to Manage Atrial Fibrillation Secondary to Ibrutinib

Hani Essa et al. JACC CardioOncol. 2021.

. 2021 Mar 16;3(1):140-144.

doi: 10.1016/j.jaccao.2020.11.016. eCollection 2021 Mar.

Authors

Hani Essa¹, Taha Lodhi², Rebecca Dobson¹, David Wright¹, Gregory Y H Lip^{1

3}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
² Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
³ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

PMID: 34396314
PMCID: PMC8352308
DOI: 10.1016/j.jaccao.2020.11.016

No abstract available

Keywords: AF, atrial fibrillation; BTK, Bruton’s tyrosine kinase; DOAC, direct oral anticoagulant; ECG, electrocardiogram; LMWH, low molecular weight heparin; OR, odds ratio; arrhythmia; echocardiography; treatment.

PubMed Disclaimer

Conflict of interest statement

Dr. Wright has received consultancy and speaker fees from Boston Scientific and Medtronic. Prof. Lip has received consultancy and speaker fees from Bayer, Bayer/Janssen, Bristol Myers Squibb/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

**Figure 1**
The ABC Pathway Applied to Oncology Patients The ABC (AF Better Care) pathway can be used to provide holistic management of atrial fibrillation (AF) patients. Step A focuses on avoiding stroke via utilization of the CHA₂DS₂-VASc score and treatment of modifiable bleeding risk factors via the HAS-BLED score. Step B focuses on symptom control in AF and the decision between rate versus rhythm control. Step C focuses on management of modifiable cardiovascular risk factors. Hb = hemoglobin; INR = international normalized ratio.

See this image and copyright information in PMC

Cited by

Palpitations in the Cancer Patient.
Essa H, Lip GY. Essa H, et al. Eur Cardiol. 2021 Dec 2;16:e45. doi: 10.15420/ecr.2021.44. eCollection 2021 Feb. Eur Cardiol. 2021. PMID: 34950241 Free PMC article. Review.
Anticoagulation in Patients With Cancer.
Piazza G. Piazza G. JACC Case Rep. 2024 Nov 20;29(22 Suppl):102684. doi: 10.1016/j.jaccas.2024.102684. eCollection 2024 Nov 20. JACC Case Rep. 2024. PMID: 39790114 Free PMC article. No abstract available.
Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk.
Erblich T, Manisty C, Gribben J. Erblich T, et al. Case Rep Hematol. 2024 Jul 9;2024:2312182. doi: 10.1155/2024/2312182. eCollection 2024. Case Rep Hematol. 2024. PMID: 39015770 Free PMC article.
Severe Spontaneous Echocardiographic Contrast in a Patient With Normal Heart and Chronic Lymphocytic Lymphoma.
Prasad RM, Layne J, Oleski M, Rodriguez L, Grimm R, Klein A, Cutler D, Collier P. Prasad RM, et al. CASE (Phila). 2023 May 28;7(7):273-277. doi: 10.1016/j.case.2023.03.005. eCollection 2023 Jul. CASE (Phila). 2023. PMID: 37546363 Free PMC article.
Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.
Wei C, Fazal M, Loh A, Kapoor R, Gomez SE, Shah S, Rogers AJ, Narayan SM, Wang PJ, Witteles RM, Perino AC, Cheng P, Rhee JW, Baykaner T. Wei C, et al. J Interv Card Electrophysiol. 2024 Jan;67(1):111-118. doi: 10.1007/s10840-023-01575-z. Epub 2023 May 31. J Interv Card Electrophysiol. 2024. PMID: 37256462 Free PMC article.

See all "Cited by" articles

References

1. Shah S., Norby F.L., Datta Y.H. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2:200–209. - PMC - PubMed
1. Ganatra S., Sharma A., Shah S. Ibrutinib-associated atrial fibrillation. J Am Coll Cardiol EP. 2018;4:1491–1500. - PubMed
1. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:2768–2801. - PubMed
1. Perez M.V., Mahaffey K.W., Hedlin H. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–1917. - PMC - PubMed
1. Malavasi V.L., Fantecchi E., Gianolio L. Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med. 2019;59:27–33. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Shah S., Norby F.L., Datta Y.H. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2:200–209. - PMC - PubMed

[2] Shah S., Norby F.L., Datta Y.H. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2:200–209. - PMC - PubMed

[3] Ganatra S., Sharma A., Shah S. Ibrutinib-associated atrial fibrillation. J Am Coll Cardiol EP. 2018;4:1491–1500. - PubMed

[4] Ganatra S., Sharma A., Shah S. Ibrutinib-associated atrial fibrillation. J Am Coll Cardiol EP. 2018;4:1491–1500. - PubMed

[5] Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:2768–2801. - PubMed

[6] Zamorano J.L., Lancellotti P., Rodriguez Muñoz D. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:2768–2801. - PubMed

[7] Perez M.V., Mahaffey K.W., Hedlin H. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–1917. - PMC - PubMed

[8] Perez M.V., Mahaffey K.W., Hedlin H. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–1917. - PMC - PubMed

[9] Malavasi V.L., Fantecchi E., Gianolio L. Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med. 2019;59:27–33. - PubMed

[10] Malavasi V.L., Fantecchi E., Gianolio L. Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med. 2019;59:27–33. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

How to Manage Atrial Fibrillation Secondary to Ibrutinib

Affiliations

How to Manage Atrial Fibrillation Secondary to Ibrutinib

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources